Canine Survivability by Breed: Ardent’s K9-ACV Registry
September 22, 2022
Canine Survivability by Breed: Ardent’s K9-ACV Registry
Ardent Animal Health (Lexington, KY) and researchers from the University of Kentucky Markey Cancer Center have developed a customized cancer treatment for dogs, known as K9-ACV1. The aim of this vaccine is to trigger the canine patients’ immune system to identify the cancer as a foreign invader. The safety and efficacy of this vaccine are not yet formally established, and these treatments are delivered under 9 CFR 103.3 via USDA Center for Veterinary Biologics oversight, and through supervision/prescription of a licensed veterinarian. A formal clinical trial featuring blinded randomization of patients’ responses associated to the standard of care has been submitted for formal licensure.
Ardent has begun capturing the real-world outcomes associated with administration of their K9-ACV vaccine, and subsequent survivability of their canine patients. In this example of real-world evidence, patients were subdivided by breed, and their survival post diagnosis was plotted. The resulting graph shows a growing divergence in postdiagnosis lifespan of different canine breeds. For example, Rottweilers (n=5) experienced a median of 336 days of survival after their cancer diagnosis, while Labrador Retrievers (n=16) had a median survival of only 148.5 days, or roughly half as long. Overall, the data suggests that as genetic variation exists across canine breeds, it may impact the outcomes of cancer treatments. In addition to breed specific survival, Ardent is tracking long-term survival of approximately 1,000 dogs median survival times across a variety of cancer types.
As a greater quantity of data is collected, and further correlations are made, Ardent Animal Health hopes that these data will help veterinarians and their patient’s families make more informed choices about cancer treatment. Additionally, real world cancer disease progression in dogs can also inform future human studies. Ardent and its fund Breakthru Strategies (Milwaukee, WI) are committed to bridging the gap between human and animal health. Its partnered mission is to strengthen the human-animal bond, while positively impacting innovation in human and animal health.
Find out more about Ardent or its K9-ACV Therapy here: https://ardentanimalhealth.com/canine-cancer/
[1] Yannelli JR, Wouda R, Masterson TJ, et al. Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs. Vet Immunol Immunopathol. 2016;182:95-100. doi:10.1016/j.vetimm.2016.10.011
Canine Survivability by Breed: Ardent’s K9-ACV Registry
September 22, 2022
Ardent Animal Health (Lexington, KY) and researchers from the University of Kentucky Markey Cancer Center have developed a customized cancer treatment for dogs, known as K9-ACV1. The aim of this vaccine is to trigger the canine patients’ immune system to identify the cancer as a foreign invader. The safety and efficacy of this vaccine are not yet formally established, and these treatments are delivered under 9 CFR 103.3 via USDA Center for Veterinary Biologics oversight, and through supervision/prescription of a licensed veterinarian. A formal clinical trial featuring blinded randomization of patients’ responses associated to the standard of care has been submitted for formal licensure.
Ardent has begun capturing the real-world outcomes associated with administration of their K9-ACV vaccine, and subsequent survivability of their canine patients. In this example of real-world evidence, patients were subdivided by breed, and their survival post diagnosis was plotted. The resulting graph shows a growing divergence in postdiagnosis lifespan of different canine breeds. For example, Rottweilers (n=5) experienced a median of 336 days of survival after their cancer diagnosis, while Labrador Retrievers (n=16) had a median survival of only 148.5 days, or roughly half as long. Overall, the data suggests that as genetic variation exists across canine breeds, it may impact the outcomes of cancer treatments. In addition to breed specific survival, Ardent is tracking long-term survival of approximately 1,000 dogs median survival times across a variety of cancer types.
As a greater quantity of data is collected, and further correlations are made, Ardent Animal Health hopes that these data will help veterinarians and their patient’s families make more informed choices about cancer treatment. Additionally, real world cancer disease progression in dogs can also inform future human studies. Ardent and its fund Breakthru Strategies (Milwaukee, WI) are committed to bridging the gap between human and animal health. Its partnered mission is to strengthen the human-animal bond, while positively impacting innovation in human and animal health.
Find out more about Ardent or its K9-ACV Therapy here: https://ardentanimalhealth.com/canine-cancer/
[1] Yannelli JR, Wouda R, Masterson TJ, et al. Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs. Vet Immunol Immunopathol. 2016;182:95-100. doi:10.1016/j.vetimm.2016.10.011
